Baxter International (BAX)
(Delayed Data from NYSE)
$35.17 USD
-0.26 (-0.73%)
Updated May 16, 2024 04:00 PM ET
After-Market: $35.17 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BAX 35.17 -0.26(-0.73%)
Will BAX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BAX
Baxter's (BAX) Clinolipid Gets FDA's Expanded Indication
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
BAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Compared to Estimates, Baxter (BAX) Q1 Earnings: A Look at Key Metrics
Baxter (BAX) Q1 Earnings Beat Estimates, '24 EPS View Raised
Other News for BAX
Baxter International Inc. stock underperforms Thursday when compared to competitors
Baxter Announces Mission and Logo for Proposed Kidney Care Company Vantive
Baxter says Vantive separation expected in second half of 2024
Nuwellis Announces Expansion of Ultrafiltration Program to Pediatric Patients at One of the Largest Hospital Networks in Florida
Baxter's Clinolipid gets FDA approval for use in infants